Teva Pharmaceutical Industries | TEVA - Cash And Equivalent


Teva Pharmaceutical Industries reported $3.56B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Aspen Pharmacare ZAR 5.62B 789M Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Dr.Reddys Laboratories INR 18.66B 8.75B Dec/2025
Guangzhou Baiy CNY 12.33B 2.61B Mar/2026
Jiangsu Hengrui CNY 40.96B 591.41M Dec/2025
Kalbe Farma IDR 4.39T 344.8B Mar/2026
Richter Gedeon HUF 135.63B 61.59B Dec/2024
Sh Fosun Pharma CNY 13.1B 1.63B Dec/2025
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025